MacroGenics

Yahoo Finance • 13 days ago

After-Hours Gainers: MGNX, SLS, KRMD, HYPR, WVE Post Sharp Moves Following Q3 Updates

(RTTNews) - Several small-cap healthcare and biotech names posted notable price increases in after-hours trading on Wednesday, following earnings updates or ahead of scheduled financial disclosures. MacroGenics, Inc. (MGNX) rose 10.2% to... Full story

Yahoo Finance • 14 days ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending devel... Full story

Yahoo Finance • 20 days ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, Pr... Full story

Yahoo Finance • last month

3 Promising Penny Stocks With Market Caps Over $100M

Major stock indexes in the United States recently ended a mixed session, with the Dow Jones Industrial Average closing at a record high amid a flurry of corporate earnings reports. For investors seeking opportunities beyond the blue-chip s... Full story

Yahoo Finance • 2 months ago

What's going on in today's after hours session

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT SPRC [https://www.chartmill.co... Full story

Yahoo Finance • 3 months ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ P... Full story

Yahoo Finance • 3 months ago

Thursday's after hours session: top gainers and losers

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] GAINERS TICKER CHANGE COMMENT MODV [https://www.chartmill.com/stock/quote/MODV/... Full story

Yahoo Finance • 3 months ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents... Full story

Yahoo Finance • 3 months ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective a... Full story

Yahoo Finance • 4 months ago

STNG Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of Scorpio Tankers Inc (Symbol: STNG) crossed above their 200 day moving average of $45.95, changing hands as high as $47.89 per share. Scorpio Tankers Inc shares are currently trading up about 2.7% on the... Full story

Yahoo Finance • 5 months ago

MacroGenics' SWOT analysis: biotech firm's stock faces pivotal year ahead

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics, finds itself at a critical juncture as it navigates through a challenging biotech landscape. Acc... Full story

Yahoo Finance • 6 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment... Full story

Yahoo Finance • 6 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC,... Full story

Yahoo Finance • 7 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of... Full story

Yahoo Finance • 8 months ago

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase... Full story

Yahoo Finance • 9 months ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment... Full story

Yahoo Finance • 9 months ago

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment o... Full story

Yahoo Finance • 10 months ago

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of MacroGenics, Inc. (NASDAQ: MGNX), Apellis P... Full story

Yahoo Finance • 2 years ago

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED)

Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday? (CORRECTED) Editor’s note: This story has been updated to correct an error in the price a... Full story

Yahoo Finance • 2 years ago

Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago

It is a pleasure to report that the MacroGenics, Inc. (NASDAQ:MGNX) is up 74% in the last quarter. But that doesn't change the fact that the returns over the last three years have been disappointing. In that time, the share price dropped 6... Full story